Step 1 topics → Hematology and Oncology → Blood Products and ABO Compatibility

Blood Products and ABO Compatibility

USMLE Step 1 trap: Applies the O universal donor rule to plasma instead of recognizing AB as universal plasma donor. Type O is the universal RBC donor, but type AB is the universal plasma donor because AB plasma contains neither anti-A nor anti-B antibodies.

Blood products and ABO compatibility is one of those topics where the details matter — the exam won't just ask you to name the products, it'll ask you to pick the right one for a clinical scenario or identify the correct donor type in a transfusion emergency. USMLE Step 1 tests this through a mix of direct recall (what does cryoprecipitate contain?) and application questions (which product do you give a patient with TTP undergoing plasmapheresis?). The ABO compatibility rules get tested in passage-based vignettes where a patient needs an emergency transfusion and you have to reason through which product is safe.

The biggest trap here is the universal donor confusion. Most students correctly memorize that type O is the universal RBC donor, then incorrectly apply that same rule to plasma — that's backwards and exactly what the exam exploits. The other common gap is around platelets: students either assume platelets need the same strict ABO/Rh matching as RBCs, or they assume no compatibility rules apply at all. Neither is right, and the nuance matters.

Finally, FFP indications trip up students who think it's appropriate to give FFP whenever an INR is elevated. USMLE Step 1 specifically tests the distinction between active coagulopathic bleeding (where FFP is indicated) versus asymptomatic lab abnormalities (where it is not). Getting clear on what each product contains and when each is actually used will carry you through these questions.

From real student decks
89%have cards covering this topic
76%have mature cards

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: Type O is the universal donor for both RBCs and plasma.
Right: Type O is the universal RBC donor, but type AB is the universal plasma donor because AB plasma contains neither anti-A nor anti-B antibodies.
The universal donor rule flips depending on which component you're transfusing. For RBCs, you're worried about antibodies in the recipient attacking donor RBC surface antigens — type O RBCs have no A or B antigens, so anyone can receive them. For plasma, the concern reverses: you're transfusing antibodies in the donor plasma, which can attack recipient RBC antigens. Type AB plasma contains neither anti-A nor anti-B antibodies, making it safe for any recipient. Memorize the flip: O for RBCs, AB for plasma.
Common mistake
Gap: Missing the ABO and Rh compatibility rules specific to platelet transfusions
Platelets are ideally ABO-matched but can be given across ABO groups in emergencies; they do not carry Rh antigens, so RhoGAM is not required for platelet transfusions.
Platelets do express ABO antigens on their surface, so ABO-matched platelets are preferred when available — mismatched platelets may have reduced survival in the recipient. However, platelets do not carry Rh antigens (D antigen is on RBC membranes, not platelets), so Rh incompatibility is not a concern and RhoGAM is not required for platelet transfusions. In emergencies, platelets can be given across ABO groups, unlike pRBCs where compatibility is more strictly enforced.
Common mistake
Wrong: FFP is indicated to correct a mildly elevated INR before routine procedures.
Right: FFP is indicated for active bleeding with coagulopathy, urgent warfarin reversal, or TTP (as replacement fluid in plasmapheresis), not for asymptomatic INR elevation.
FFP contains all clotting factors and is indicated when a patient is actively bleeding due to factor deficiency or coagulopathy, or when warfarin reversal is urgently needed. A mildly elevated INR in an asymptomatic patient does not warrant FFP — the risks of transfusion (volume overload, TRALI, infections) outweigh any theoretical benefit from prophylactic factor replacement when there's no active bleeding. The specific TTP indication (FFP as replacement fluid in plasmapheresis) is a high-yield exception that gets tested separately.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the clinical indications for each blood product: pRBCs (symptomatic anemia or acute hemorrhage), FFP (active coagulopathy, urgent warfarin reversal, TTP plasmapheresis replacement), cryoprecipitate (hypofibrinogenemia, hemophilia A, vWD, DIC), and platelets (thrombocytopenia with active bleeding or count below threshold for procedures).
  2. Understand and apply the universal donor and recipient rules separately for RBCs and plasma: type O negative is the universal RBC donor, but type AB is the universal plasma donor because AB plasma has neither anti-A nor anti-B antibodies — and know why these rules are different.

Can you avoid these mistakes?

A patient with TTP is being treated with plasmapheresis. Which blood product is used as the replacement fluid, and why?
In a trauma bay, you have no time to type and cross — you need to give emergency RBCs and emergency plasma. Which ABO types do you reach for, and are they the same type?
A patient on warfarin has an INR of 2.4 and is scheduled for elective knee replacement tomorrow. The surgical team asks about giving FFP tonight to 'normalize' the INR. Is this appropriate? What would be the right management instead?
A thrombocytopenic patient needs a platelet transfusion urgently but no ABO-matched platelets are available. Can you give ABO-mismatched platelets? Do you need to give RhoGAM afterward?

Related topics

Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →